DPP-4 inhibitor effective and safe in T2DM
The CARMELINA trial, evaluating long-term safety outcomes of DPP-4 inhibitor linagliptin vs placebo in T2DM adults, many of whom had kidney disease, met its primary endpoint, showing CV safety.
ReferencesNews - July 26, 2018
The CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with type 2 diabetes at high vascular risk (CARMELINA) study met its primary endpoint, and demonstrated similar cardiovascular (CV) safety outcomes after treatment with the DPP-4 inhibitor linagliptin in T2DM patients, compared to placebo.
The CARMELINA study was a randomized, double-blind, placebo-controlled clinical trial, evaluating the long-term effect of linagliptin on CV safety in 6,979 adult T2DM patients at high CV risk, the majority of whom also had kidney disease, for a duration of 2.2 years.
The primary outcome of the study consisted of time to first occurrence of CV death, non-fatal myocardial infarction or non-fatal stroke (3-point MACE) after treatment with either 5 mg once daily linagliptin or placebo, both added on top of standard care (glucose-lowering drugs and CV drugs, including antihypertensive and lipid-lowering agents). The overall safety profile of linagliptin in CARMELINA, including adults with kidney disease, was consistent with previous data and no new safety signal was observed.
The DPP-4 inhibitor linagliptin, prescribed as one dose, significantly reduces blood glucose levels in T2DM adults and can be prescribed for individuals with T2DM, regardless of age, disease duration, ethnicity, BMI, and liver and kidney function and has demonstrated proven efficacy regardless of kidney function.
Results of the CARMELINA study will be presented on 4 October at 54th European Association for the study of Diabetes Annual Meeting in Berlin, Germany.
References
1 Bhatnagar D, Durrington PN. Omega-3 fatty acids: their role in the prevention and treatment of atherosclerosis related risk factors and complications. International Journal of Clinical Practice 2003;57(4):305–14.
2 British Nutrition Foundation. N-3 fatty acids and health. London: British Nutrition Foundation; 1999. Briefing paper.
3 Calabresi L, Villa B, Canavesi M, Sirtori CR, James RW, Bernini F, et al. An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia. Metabolism 2004;53(2):153–8.
4 Chang CL, Deckelbaum RJ. Omega-3 fatty acids: mechanisms underlying “protective effects” in atherosclerosis. Current Opinion in Lipidology 2013;24(4): 345–50. DOI: 10.1097/MOL.0b013e3283616364
5 Geelen A, Brouwer IA, Zock PL, Katan MB. Antiarrhythmic effects of n-3 fatty acids: evidence from human studies. Current Opinion in Lipidology 2004;15:25–30.
6 American Heart Association. Fish and Omega-3 Fatty Acids. heart.org/HEARTORG/HealthyLiving/ HealthyEating/HealthyDietGoals/Fish-and-Omega-3Fatty-Acids UCM 303248 Article.jsp#.WhfuRzenzIU (accessed 24 November 2017).